Zyprexa [金普薩] - Taiwan - 全球药品采购网

TOP

Zyprexa [金普薩]

2015-01-29 16:07:00 来源: 作者: 【大中小】浏览:791次评论:0条

全民健康保險藥品給付規定 / 健保碼及健保價

See related Zyprexa[金普薩] information

製造商

Eli Lilly

代理/經銷商

Eli Lilly

成份

Olanzapine

適應症

Tab Olanzapine is indicated for the treatment of schizophrenia. Olanzapine is effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response. Olanzapine is indicated for the treatment of moderate to severe manic episode. In patients whose manic episode has responded to olanzapine treatment, olanzapine is indicated for the prevention of recurrence in patients with bipolar disorder. Vial Rapid control of agitation & disturbed behaviours in patients with schizophrenia or manic episode, when oral therapy is not appropriate.

用量

Tab Adult Schizophrenia Starting dose: 10 mg/day. Manic episodes Starting dose: 15 mg as a single daily dose in monotherapy or 10 mg daily in combination therapy. Preventing recurrence in patients whose manic episodes have responded previously to olanzapine Starting dose: 10 mg daily. Dose range for all indications: 5-20 mg daily. A lower starting dose (5 mg/day) should be considered for elderly patients (> 65 years) & in renal or hepatic impairment. Vial Initially, 10 mg as single IM inj. Max: 20 mg (including all formulations), not more than 3 inj per 24-hr period.

用法

May be taken with or without food

美國食品藥物管理局之懷孕等級

Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or embryocidal or other) and there are no controlled studies in women or studies in women and animals are not available. Drugs should be given only if the potential benefit justifies the potential risk to the foetus.

禁忌

Narrow-angle glaucoma.

注意事項

Hyperglycemia & diabetes; prostatic hypertrophy; paralytic ileus & related conditions; hepatic impairment; patients with low leukocyte &/or neutrophil counts; history of or existing bone marrow depression; hypereosinophilic conditions or with myeloproliferative disease; history of seizures; tardive dyskinesia. Periodic monitoring of BP in patients > 65 years. Pregnancy, lactation. Neuroleptic malignant syndrome; worsening of Parkinsonian symtomatology & hallucinations; not approved for the treatment of dementia-related psychosis &/or behavioural disturbances; transient, asymtomatic elevations of hepatic ALT, AST. Lipid alterations should be managed as clinically appropriate. Avoid abrupt withdrawal. Avoid in rare hereditary problems of galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption. May affect ability to operate machinery or drive motor vehicles.

不良反應

Somnolence, weight gain, dizziness, akathisia, parkinsonism, dyskinesia, increased appetite, elevated glucose & triglyceride levels, asthenia, edema, orthostatic hypotension, dry mouth, constipation, eosinophilia, elevated prolactin levels (but clinical manifestations rare), cholesterol, glucosuria, anticholinergic effects, transient asymptomatic elevations of hepatic transaminases, rash, fatigue. Elderly patients with dementia: a higher incidence of death & cerebrovascular adverse events; abnormal gait & falls; Pneumonia & urinary incontinence, increased body temp, lethargy, erythema, visual hallucinations. Additionally for inj, bradycardia with or without hypotension or syncope, tachycardia, postural hypotension, hypotension, inj site discomfort.
View ADR Monitoring Website[參閱藥物不良反應監測表格]

交互作用

May enhance the effects of alcohol & other CNS depressants. Use with drugs that inhibit or induce CYP1A2 may affect plasma concentrations of olanzapine. May antagonise the effects of dopamine agonists. Clearance is increased by smoking or carbamazepine administration. Bioavailability reduced with concomitant use of activated charcoal. Fluvoxamine significantly inhibits the metabolism of olanzapine, consider lowering the dose of olanzapine.
View more drug interactions with Zyprexa[金普薩]

本商品之市售規格

劑型

包裝

圖片

Zyprexa 膜衣錠